Clinical Trials

The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed.

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

This study will test the feasibility and acceptability of deploying a decision aid for surrogate decision makers of comatose survivors of cardiac arrest early during hospitalization.

The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed.

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.

Are you an adult with ischemic or non-ischemic cardiomyopathy? This observational study will group and follow patients at a higher risk for sudden cardiac death (SCD) who receive an implantable cardioverter defibrillator (ICD) pulse generator replacement as a prevention measure. The study hypothesizes that abnormalities of the heart, some of which are genetically determined, can be used to identify patients at high risk of SCD. To participate in this study, you must be between 18 and 85 years old and have ischemic or non-ischemic cardiomyopathy. You must also be getting your initial ICD implant for primary prevention or a programmed generator replacement if the ICD was originally implanted for SCD primary prevention. The study takes place in Baltimore, Maryland; Richmond, Virginia; and Washington, DC.

Are you an adult with ischemic cardiomyopathy? This study is investigating ways to prevent sudden cardiac arrest in people with ischemic cardiomyopathy. Researchers in this study are also working to determine which patients could benefit from an implantable cardioverter defibrillator, a device that is connected to the heart that can detect and stop irregular heartbeats called arrythmias. To participate in this study, you must be 18 years old or older and have ischemic cardiomyopathy. This study takes place in Buffalo, New York.

Are you a woman who is postmenopausal or a man older than 65? This study will investigate the effects of oral progesterone for older women and testosterone for older men on QT intervals. QT intervals that are increased by medicine can lead to dangerous heart rhythm problems. Researchers hope to learn more about why this happens and how to deliver safer doses. This study is located in Indianapolis, Indiana.

The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 10 participants.

The Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Study is an ancillary study from the parent study, DCM Precision Medicine Study. The rationale for the DCM-CMR study is to leverage cardiac magnetic resonance (CMR) imaging to detect earliest findings of DCM in the at-risk family members enrolled into the parent study.